We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Enclomiphene citrate — the trans-isomer of clomiphene (SERM)
The trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) used investigationally as a testosterone therapy. By blocking estrogen feedback at the hypothalamus it raises LH, FSH, and endogenous testosterone. Honest appraisal: Phase-2/3 RCTs show it raises testosterone — but it is NOT FDA-approved (Androxal failed to gain approval) and is compounded, and there are NO long-term hard-outcome trials (cardiovascular, bone, mortality).
Prescription medication — not a dietary supplement
Enclomiphene is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Enclomiphene doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from medium-quality meta-analyses and randomised trials published 2013–2025 with a typical study size of 15 participants.
Based on 8 studies · 1 meta-analysis · 3 RCTs · 75 total participants
Confidence
Moderate confidenceBy outcome
Phase-2 and Phase-3 randomized trials consistently show enclomiphene raises endogenous testosterone (via increased LH/FSH). But it is NOT FDA-approved (Androxal failed to gain approval) and is used compounded, the trials are short-term and surrogate-endpoint-based, and there are NO long-term hard-outcome data (cardiovascular, bone, mood, mortality), which keeps it emerging.
17 trials ongoing or recruiting · 162 completed on ClinicalTrials.gov
28 of the completed trials have posted results
Registered trials show research momentum for Enclomiphene, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Enclomiphene citrate is the trans-stereoisomer of clomiphene citrate, a non-steroidal selective estrogen receptor modulator (SERM).
Clomiphene — long FDA-approved for ovulation induction in women and used off-label in men with low testosterone — is a mixture of two isomers: zuclomiphene (cis, long half-life, weakly estrogenic) and enclomiphene (trans, the estrogen-antagonist isomer that drives most of the testosterone-raising effect).
The premise of enclomiphene is to deliver clomiphene's beneficial trans-isomer effect without accumulating the long-lived zuclomiphene.
Mechanistically it blocks estrogen-receptor feedback at the hypothalamus and pituitary, which the brain reads as low estrogen, so it increases pulsatile GnRH and therefore pituitary LH and FSH.
Higher LH stimulates testicular Leydig cells to make more testosterone, and higher FSH supports Sertoli-cell-driven spermatogenesis.
The key clinical contrast is with exogenous testosterone (gels, injections): replacement testosterone raises serum testosterone but suppresses the hypothalamic-pituitary-testicular axis, dropping LH/FSH and impairing sperm production — a problem for men who want to preserve fertility.
Enclomiphene instead 'restores' rather than 'replaces': in Phase-2 and Phase-3 randomized trials (the Repros/Androxal program), oral enclomiphene raised total testosterone into the normal range comparably to topical testosterone, while — unlike the gel — it raised LH and FSH and kept sperm concentrations in the normal range.
In the cited trials in men with secondary hypogonadism, enclomiphene increased testosterone while sperm concentration was maintained. These outcomes do not establish a guarantee of fertility, pregnancy or live birth. The honest limits are significant.
In 2018, the European Medicines Agency recommended refusal of the EnCyzix application for enclomifene. This decision relates to that product and application. SupStack does not recommend self-directed enclomiphene use.
Despite positive Phase-3 testosterone/sperm data, Androxal did not gain FDA approval (the agency's concerns centered on the indication, study endpoints, and estradiol/clinical-benefit questions), so what men actually use today is compounded enclomiphene — variable in quality and dose.
The evidence base is short-term (weeks to a few months) and built around surrogate endpoints (testosterone, LH/FSH, sperm count).
There are NO long-term outcome trials: no data on cardiovascular events, bone mineral density, mood, or mortality over years of use, and SERMs as a class carry plausible concerns (e.g. thromboembolism, visual effects, mood changes with clomiphene).
The cited randomised trials support changes in testosterone and sperm concentration in the studied men. They do not establish pregnancy or live-birth benefit or long-term safety. Regulatory status must be stated by jurisdiction. This is a hormonal compound, not a longevity agent.
As the trans-isomer of clomiphene, enclomiphene antagonizes estrogen receptors at the hypothalamus and pituitary. The brain reads this as low estrogen and releases the negative feedback that normally restrains GnRH.
Removing estrogen feedback increases pulsatile GnRH, driving the pituitary to secrete more luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — the opposite of what exogenous testosterone does.
Higher LH stimulates testicular Leydig cells to make testosterone; higher FSH supports Sertoli-cell-driven sperm production. The result is restored testosterone. A change or preservation of sperm counts in a particular trial does not guarantee fertility or a pregnancy. Any study finding should be read with its preparation, comparator and duration.
How Enclomiphene works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Trials in selected men with secondary hypogonadism found that enclomiphene could raise testosterone while maintaining sperm concentrations. This does not establish preservation of fertility while continuing exogenous testosterone or guarantee pregnancy. Men who want current or future fertility should discuss options with a fertility specialist before starting testosterone.
Unlikely to help — enclomiphene works by driving an intact pituitary-testis axis; it cannot rescue failed testes.
No long-term cardiovascular or thrombosis outcome data exist; weigh the unknown long-term risk.
Use is clinician-directed; enclomiphene is a male therapy, but any fertility-related use should be supervised.
Exogenous androgens suppress the hypothalamic-pituitary axis that enclomiphene works through; combining them is contradictory. Using testosterone can suppress sperm production. Discuss treatment and fertility goals with the prescriber.
Overlapping effects on the estrogen/HPG axis; stacking them is common in TRT circles but is not validated and can produce unpredictable estradiol and lipid effects.
Estrogen supplementation works against enclomiphene's mechanism (it blocks estrogen-receptor feedback) and would blunt the testosterone response.
Tip: A known clomiphene-class effect; stop and seek care if vision changes — usually reversible.
Tip: Reported with clomiphene-class SERMs; monitor and discuss with the prescribing clinician.
Tip: Usually transient; were generally comparable to testosterone gel and placebo in the short-term trials.
Tip: A plausible class concern for SERMs; long-term risk in men is not characterized. Chest pain, sudden breathlessness, coughing up blood or collapse: call emergency services now. Sudden swelling of one leg or a warm, painful calf: get urgent medical assessment today.
Enclomiphene has an evidence score of 4.2/10 — emerging evidence based on 8 indexed studies. The trans-isomer of clomiphene — a selective estrogen receptor modulator (SERM) used investigationally as a testosterone therapy. By blocking estrogen feedback at the hypothalamus it raises LH, FSH, and endogenous testosterone. Honest appraisal: Phase-2/3 RCTs show it raises testosterone — but it is NOT FDA-approved (Androxal failed to gain approval) and is compounded, and there are NO long-term hard-outcome trials (cardiovascular, bone, mortality). Representative study: PMID 26496621.
Dosing for Enclomiphene: Investigational — no FDA-approved dose exists. The cited phase 2 and phase 3 trials gave oral enclomiphene citrate once daily, and neither abstract states the doses used. Compounded enclomiphene is used under a clinician at similar doses, but quality and content are not regulated. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Enclomiphene — consistent daily use matters more than the time of day. Studied as a once-daily oral dose.
Enclomiphene should be used with caution — talk to a healthcare provider before taking it. Reported side effects include venous thromboembolism, visual disturbances (blurring, flashes, floaters), mood changes / irritability. How often they occur is not established for all of them. Use caution if any of these apply to you: Primary (testicular) hypogonadism — needs an intact pituitary/testis axis to work; Hormone-sensitive tumors or conditions worsened by raising testosterone/estrogen; History of venous thromboembolism (class concern for SERMs).
What side effects does Enclomiphene have?Don't take this if…
Testosterone (TRT)
Too few graded studiesThe primary male androgen and a prescription medicine with US FDA-approved products for specified causes of male hypogonadism, and a Schedule III controlled substance in the US. For men with genuinely low testosterone, randomized trials show real benefits: the Testosterone Trials (TTrials) improved sexual function, mood, anemia and bone density in older hypogonadal men, and the large TRAVERSE trial found TRT non-inferior to placebo for major cardiac events. But those benefits were modest and indication-specific, NOT a longevity or anti-aging result. It is prescription-only in Germany and Austria. Non-medical, supraphysiologic and 'anti-aging' use is not established as safe or effective for longevity and carries serious harms — erythrocytosis, suppressed sperm production/fertility, cardiovascular and psychiatric risk. This is a harm-reduction reference, not a recommendation, and testosterone is NOT a dietary supplement.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
DHEA
Probably helpsAdrenal hormone precursor that declines with age. In postmenopausal women with normal adrenal function, trials found no effect on sexual symptoms or metabolic markers.
Tamoxifen (Nolvadex)
Too few graded studiesA selective estrogen receptor modulator (SERM) and one of the most successful cancer drugs ever made: in estrogen-receptor-positive breast cancer, five years of adjuvant tamoxifen cuts 15-year recurrence by roughly half and breast-cancer death by about a third (EBCTCG), and it prevents breast cancer in high-risk women (NSABP P-1). Among men it is used OFF-LABEL — it antagonizes estrogen in breast tissue to prevent or treat gynecomastia (well-supported by RCTs during antiandrogen therapy, and in idiopathic/pubertal cases), and it blocks estrogen feedback at the hypothalamus to raise LH/FSH and endogenous testosterone, which is why it appears in male-infertility regimens and bodybuilding post-cycle therapy (PCT). The honest limits are real and non-negotiable: tamoxifen raises the risk of endometrial cancer and venous thromboembolism (clots, pulmonary embolism, stroke) and can cause visual/ocular changes. It is NOT a longevity drug.
Explore: Best supplements for Men's HealthBest supplements for Women's Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 8 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research